Pfizer (NYSE:PFE) Trading Down 2.4% – Time to Sell?

Pfizer Inc. (NYSE:PFE)’s share price was down 2.4% during trading on Monday . The stock traded as low as $23.62 and last traded at $23.74. 58,429,589 shares changed hands during mid-day trading, an increase of 36% from the average session volume of 42,859,461 shares. The stock had previously closed at $24.32.

Analysts Set New Price Targets

Several analysts have issued reports on PFE shares. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. Wolfe Research reiterated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Morgan Stanley upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.59.

Pfizer Trading Down 2.4%

The firm has a market cap of $135.30 billion, a P/E ratio of 18.12 and a beta of 0.35. The stock has a 50 day moving average of $25.63 and a 200 day moving average of $26.23. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. United Bank lifted its stake in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the period. Sei Investments Co. raised its holdings in Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC grew its stake in shares of Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.